Treatment results

• 81% of the horses were treatment successes.
• 84% of those newly diagnosed with EPM were treatment successes.
• 78% of horses previously treated for EPM with other products were treatment successes.

• In Field Study I, 57% of horses receiving Navigator Paste were considered treatment successes.*

In Field Study II, 81% of the horses were successfully treated. Data submitted to FDA and on file, IDEXX Pharmaceuticals, Inc.

See the Navigator package insert, Field Study I. (245 KB)

Warnings: Administration of nitazoxanide can disrupt the normal microbial flora of the gastrointestinal tract, leading to enterocolitis. Deaths due to enterocolitis have been observed while administering the recommended dose in field studies.

Obtain an accurate body weight and calculate the dose weekly during treatment. Overdosing of nitazoxanide must be avoided. Read the Dosage & Administration and Precautions sections of the package insert before dosing the horse. It is important to monitor the horse for adverse clinical signs during treatment. Read the Adverse Reactions section of the package insert for more information on adverse reactions.